Literature DB >> 22827162

In vivo encapsulation of nucleic acids using an engineered nonviral protein capsid.

Seth Lilavivat1, Debosmita Sardar, Subrata Jana, Geoffrey C Thomas, Kenneth J Woycechowsky.   

Abstract

In Nature, protein capsids function as molecular containers for a wide variety of molecular cargoes. Such containers have great potential for applications in nanotechnology, which often require encapsulation of non-native guest molecules. Charge complementarity represents a potentially powerful strategy for engineering novel encapsulation systems. In an effort to explore the generality of this approach, we engineered a nonviral, 60-subunit capsid, lumazine synthase from Aquifex aeolicus (AaLS), to act as a container for nucleic acid. Four mutations were introduced per subunit to increase the positive charge at the inner surface of the capsid. Characterization of the mutant (AaLS-pos) revealed that the positive charges lead to the uptake of cellular RNA during production and assembly of the capsid in vivo. Surprisingly, AaLS-pos capsids were found to be enriched with RNA molecules approximately 200-350 bases in length, suggesting that this simple charge complementarity approach to RNA encapsulation leads to both high affinity and a degree of selectivity. The ability to control loading of RNA by tuning the charge at the inner surface of a protein capsid could illuminate aspects of genome recognition by viruses and pave the way for the development of improved RNA delivery systems.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827162     DOI: 10.1021/ja302743g

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  6 in total

1.  Laboratory evolution of virus-like nucleocapsids from nonviral protein cages.

Authors:  Naohiro Terasaka; Yusuke Azuma; Donald Hilvert
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

2.  Evolution of a designed protein assembly encapsulating its own RNA genome.

Authors:  Gabriel L Butterfield; Marc J Lajoie; Heather H Gustafson; Drew L Sellers; Una Nattermann; Daniel Ellis; Jacob B Bale; Sharon Ke; Garreck H Lenz; Angelica Yehdego; Rashmi Ravichandran; Suzie H Pun; Neil P King; David Baker
Journal:  Nature       Date:  2017-12-13       Impact factor: 49.962

3.  The C-terminal peptide of Aquifex aeolicus riboflavin synthase directs encapsulation of native and foreign guests by a cage-forming lumazine synthase.

Authors:  Yusuke Azuma; Reinhard Zschoche; Donald Hilvert
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

4.  Evolution of a virus-like architecture and packaging mechanism in a repurposed bacterial protein.

Authors:  Stephan Tetter; Naohiro Terasaka; Angela Steinauer; Richard J Bingham; Sam Clark; Andrew J P Scott; Nikesh Patel; Marc Leibundgut; Emma Wroblewski; Nenad Ban; Peter G Stockley; Reidun Twarock; Donald Hilvert
Journal:  Science       Date:  2021-06-11       Impact factor: 47.728

Review 5.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

Review 6.  Second career of a biosynthetic enzyme: Lumazine synthase as a virus-like nanoparticle in vaccine development.

Authors:  Rudolf Ladenstein; Ekaterina Morgunova
Journal:  Biotechnol Rep (Amst)       Date:  2020-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.